Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease
AssigneesInstituto Nacional de Ciencias Medicas Y Nutricion, The General Hospital Corporation, Children's Hospital Medical Center
InventorsArdythe L. Morrow, Guillermo Ruiz-Palacios, David S. Newburg
Life of this patent
Estimating the term…
Abstract
An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
Claims15
A method for identifying and reducing the risk of an individual for developing sepsis or for developing a gastrointestinal infectious disorder or gastrointestinal inflammatory disorder, the method comprising:
- (a) measuring the level of at least one antigen in a biological sample from the individual, the at least one antigen being H-1, H-2, Lewisb, Lewisy, sulfated or sialylated H-1, sulfated or sialylated H-2, sialylated Lewisa, sulfated or sialylated Lewisb, or sulfated or sialylated Lewisy;
- (b) comparing the measured level of the at least one antigen to a predetermined value or a predetermined range of values,
- (c) identifying the individual as being at risk for developing sepsis or for developing a gastrointestinal infectious disorder or gastrointestinal inflammatory disorder if the measured level of the at least one antigen differs from the predetermined value or is outside the predetermined range of values, and
- (d) administering to the individual one or more of α1,2 fucosyl glycans, probiotic organisms, or prebiotics, if the individual is identified as being at risk for developing sepsis or for developing a gastrointestinal infectious disorder or gastrointestinal inflammatory disorder.
A method for reducing the risk for developing sepsis or for developing a gastrointestinal infectious disorder or gastrointestinal inflammatory disorder in a subject, the method comprising:
- (a) identifying an individual who is at risk for developing sepsis or for developing a gastrointestinal infectious disorder or gastrointestinal inflammatory disorder based on the level of at least one antigen in a biological sample from the individual, the at least one antigen being H-1, H-2, Lewisb, Lewisy, sulfated or sialylated H-1, sulfated or sialylated H-2, sialylated Lewisa, sulfated or sialylated Lewisb, or sulfated or sialylated Lewisy, wherein the level of the at least one antigen of the individual differs from a predetermined value or is outside a predetermined range of values;
- and
- (b) administering to the individual one or more of α1.2 fucosyl glycans, probiotic organisms, or prebiotics to reduce the risk in the individual of developing sepsis or developing a gastrointestinal infectious disorder or gastrointestinal inflammatory disorder if the individual is identified as being at risk for developing sepsis or for developing a gastrointestinal infectious or inflammatory disorder.
Dependencies are inferred from the claim text.